Re-Evaluating Risks and Benefits in Human Subjects Research
By Jonathan Kahn, Biopolitical Times guest contributor
| 05. 25. 2011
Modern bioethics is grounded in four basic principles: respect for persons (i.e. autonomy), beneficence, nonmalificence and justice. In a recent presentation at the 2011 ELSI Congress, "Exploring the ELSI Universe," Malia Fullerton, a professor in the Department of Bioethics & Humanities at the University of Washington School of Medicine, noted that "respect for persons" and "beneficence" have come to be the preeminent values in bioethical review of human subjects studies, particularly in the context of IRB review. Respect for persons typically manifests in a concern for informed consent, and beneficence in a concern for weighing the potential harms and benefits of research. Fullerton argued that a more balanced consideration of the other values, particularly justice and a concern for persons not just in terms of consent but in terms of dignity, needed to be incorporated into such review.
This got me to thinking about these concepts and their deployment in current biomedical research. Beneficence has often been cast in terms of balancing costs and benefits, as though it were simply a utilitarian calculus. However, in the context of...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...